APA

McCormick A. L., Moynihan L., Macartney M. J., Garcia-Diaz A., Smith C., Johnson M. A., Rodger A. J., Bhagani S., Haque T. & Webster D. P. (20160225). Baseline drug resistance mutations are detectable in HCV genes NS3 and NS5A but not NS5B in acute and chronic HIV-coinfected patients. : Antiviral therapy.

Chicago

McCormick Adele L, Moynihan Luke, Macartney Malcolm J, Garcia-Diaz Ana, Smith Colette, Johnson Margaret A, Rodger Alison J, Bhagani Sanjay, Haque Tanzina and Webster Daniel P. 20160225. Baseline drug resistance mutations are detectable in HCV genes NS3 and NS5A but not NS5B in acute and chronic HIV-coinfected patients. : Antiviral therapy.

Harvard

McCormick A. L., Moynihan L., Macartney M. J., Garcia-Diaz A., Smith C., Johnson M. A., Rodger A. J., Bhagani S., Haque T. and Webster D. P. (20160225). Baseline drug resistance mutations are detectable in HCV genes NS3 and NS5A but not NS5B in acute and chronic HIV-coinfected patients. : Antiviral therapy.

MLA

McCormick Adele L, Moynihan Luke, Macartney Malcolm J, Garcia-Diaz Ana, Smith Colette, Johnson Margaret A, Rodger Alison J, Bhagani Sanjay, Haque Tanzina and Webster Daniel P. Baseline drug resistance mutations are detectable in HCV genes NS3 and NS5A but not NS5B in acute and chronic HIV-coinfected patients. : Antiviral therapy. 20160225.